TILS-021 Study for Secondary Progressive MS
- Study HIC#:2000036470
- Last Updated:05/01/2025
The aim of this study is to prevent the immune system's attack and to dampen inflammation in the brain. The study is testing the investigational medication Foralumab, which is given as a nasal inhalation 3 times per week.
Participants will be randomly selected to receive placebo or the study drug; each participant has a 2 out of 3 chances of getting the active medication. Neither you nor your doctor will know which treatment you received. The study will include study drug, blood testing, MRIs and PET scans. The total duration of the study will be approximately 3-5 months.
To find out more or to volunteer for this trial, write to MSResearch@yale.edu or katerina.palma@yale.edu and reference the "Tiziana trial".
Contact Us
For more information about this study, including how to volunteer, contact:
Katerina Palma
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
- Age 18-75
- Diagnosis of secondary progressive MS
- Be able to walk (using a cane or walker is OK)
- Your MS has been getting worse within the last 2 years, despite having used approved MS medications in the past
You must be willing to discontinue your MS medication to qualify for this trial.
